GlassScriptPhysician profile
Rakhi Krishnan
NPI 1477578656
$639.82
in general payments reported to CMS, 2019-2025
16 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $17.34 · 2023: $105 · 2024: $219 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $455.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $130.67 | 2023-2025 | |
| Gilead Sciences, INC. | $82.02 | 2024-2025 | |
| Insmed, INC. | $61.73 | 2019 | |
| Allergan, INC. | $59.63 | 2019 | |
| Ferring Pharmaceuticals INC. | $46.62 | 2024 | Rebyota |
| Lilly USA, LLC | $44.94 | 2024-2025 | Jardiance |
| Viiv Healthcare Company | $32.95 | 2019-2023 | Rukobia |
| Shionogi INC | $32.28 | 2025 | Fetroja |
| Exact Sciences Corporation | $26.98 | 2023 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $22.58 | 2024 | Heplisav-B |
| Astrazeneca Pharmaceuticals LP | $20.27 | 2024 | Airsupra |
| Merck Sharp & Dohme LLC | $18.29 | 2023 | Verquvo, Belsomra |
| E.R. Squibb & Sons, L.L.C. | $17.34 | 2020 | |
| Novo Nordisk INC | $16.45 | 2019 | |
| Pfizer INC. | $15.66 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rakhi Krishnan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.